Kerendia (Finerenone) Contraindications
Kerendia is contraindicated in three specific situations: patients with hypersensitivity to any component of the product, those receiving concomitant treatment with strong CYP3A4 inhibitors, and patients with adrenal insufficiency. 1
Absolute Contraindications
The FDA label explicitly lists the following contraindications:
- Hypersensitivity reactions to finerenone or any component of Kerendia
- Concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, ritonavir, clarithromycin, nefazodone)
- Adrenal insufficiency
Critical Initiation Restrictions (Not Absolute Contraindications, But Important Barriers)
While not technically contraindications, the following conditions prevent initiation:
- Do NOT initiate if serum potassium > 5.0 mEq/L 1
- Do NOT initiate in heart failure patients if eGFR < 25 mL/min/1.73m² 1
Drug Interactions Requiring Avoidance
Beyond the contraindicated strong CYP3A4 inhibitors:
- Avoid grapefruit and grapefruit juice (acts as CYP3A4 inhibitor) 1
- Avoid strong or moderate CYP3A4 inducers (reduces finerenone efficacy, though not formally contraindicated) 1
Important Monitoring Requirements to Prevent Adverse Outcomes
Hyperkalemia is the primary safety concern. The drug requires:
- Baseline potassium and eGFR measurement before initiation
- Repeat potassium measurement at 4 weeks after initiation
- Periodic monitoring throughout treatment
- More frequent monitoring with concomitant medications that increase potassium (ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, potassium supplements) 1
Pregnancy considerations: While not listed as an absolute contraindication, women of childbearing potential should use contraception, particularly if also on ACE inhibitors or ARBs 2
Clinical Context
The contraindication for strong CYP3A4 inhibitors exists because these drugs significantly increase finerenone exposure, raising the risk of hyperkalemia and other adverse effects 1. The adrenal insufficiency contraindication relates to finerenone's mechanism as a mineralocorticoid receptor antagonist, which could worsen this condition.
In real-world practice, hyperkalemia leading to discontinuation occurred in only 1% of patients when proper monitoring protocols were followed 3, and no deaths from hyperkalemia were reported in major trials 4. This emphasizes that with appropriate monitoring, finerenone can be used safely even in high-risk populations.